DOCSLIB.ORG

Cphi & P-MEC China Exhibition List展商名单version版本20180116

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cphi & P-MEC China Exhibition List展商名单version版本20180116 CPhI & P-MEC China Exhibition List展商名单 Version版本 20180116 Booth/ Company Name/公司中英文名 Product/产品 展位号 Carbosynth Ltd E1A01 Toronto Research Chemicals Inc E1A08 SiliCycle Inc. E1A10 SA TOURNAIRE E1A11 Indena SpA E1A17 Trifarma E1A21 LLC Velpharma E1A25 Anuh Pharma E1A31 Chemclone Industries E1A51 Hetero Labs Limited E1B09 Concord Biotech Limited E1B10 ScinoPharm Taiwan Ltd E1B11 Dongkook Pharmaceutical Co., Ltd. E1B19 Shenzhen Salubris Pharmaceuticals Co., Ltd E1B22 GfM mbH E1B25 Leawell International Ltd E1B28 DCS Pharma AG E1B31 Agno Pharma E1B32 Newchem Spa E1B35 APEX HEALTHCARE LIMITED E1B51 AMRI E1C21 Aarti Drugs Limited E1C25 Espee Group Innovators E1C31 Ruland Chemical Co., Ltd. E1C32 Merck Chemicals (Shanghai) Co., Ltd. E1C51 Mediking Pharmaceutical Group Ltd E1C57 珠海联邦制药股份有限公司/The United E1D01 Laboratories International Holdings Ltd. FMC Corporation E1D02 Kingchem (Liaoning) Chemical Co., Ltd E1D10 Doosan Corporation E1D22 Sunasia Co., Ltd. E1D25 Bolon Pharmachem Co., Ltd. E1D26 Savior Lifetec Corporation E1D27 Alchem International Pvt Ltd E1D31 Polish Investment and Trade Agency E1D57 Fischer Chemicals AG E1E01 NGL Fine Chem Limited E1E24 常州艾柯轧辊有限公司/ECCO Roller E1E25 Linnea SA E1E26 Everlight Chemical Industrial Corporation E1E27 HARMAN FINOCHEM E1E28 Zhechem Co Ltd E1F01 Midas Pharma GmbH Shanghai Representativ E1F03 Supriya Lifescience Ltd E1F10 KOA Shoji Co Ltd E1F22 NOF Corporation E1F24 上海贺利氏工业技术材料有限公司/Heraeus E1F26 Materials Technology Shanghai Ltd. Novacyl Asia Pacific Ltd E1F28 PharmSol Europe Limited E1F32 Bachem AG E1F35 Louston International Inc. E1F51 High Science Co Ltd E1F55 Chemsphere Technology Inc. E1F57a PharmaCore Biotech Co., Ltd. E1F57b Rockwood Lithium GmbH E1G51 Sarv Bio Labs Pvt Ltd E1G57 抗病毒类、抗肿瘤类、抗感染类和甾体类中间体、原料药和药物制剂及医药合约研发和加工服务 上海创诺医药集团有限公司/Shanghai Desano APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and E1H01 Pharmaceuticals Co., Ltd. pharmaceutical CRO & CDMO service APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and pharmaceutical CRO & CDMO service 培他米松、地塞米松、泼尼松、泼尼松龙、甲泼尼龙、醋酸氢化可的松、螺内酯、氨基酸、GCLE 、7AVCA、头孢地尼、核黄素磷酸钠、甲睾酮、阿替洛尔、尼莫地平、阿加曲班、尼美舒利、阿 德福韦酯、注射用氢化可的松、注射用马来酸阿奇霉素、肝素钠注射液、注射用尿激酶、黄芪皂苷 天津市医药集团有限公司/Tianjin Tianfa I、II、III、番泻叶提取物、甜菊糖苷、萝卜硫素。Betamethasone Base, Dexamethasone Base, E1H16 Pharmaceuticals Imp. & Exp. Corp. Prednisone, Prednisolone, Methylprednisolone, Hydrocortisone Acetate, Spironolactone, Amino Acid, Budesonide, Fluocinolone Acetonide, Fluocinonide, Triamcinolone Base, Triamcinolone Acetonide, Halcinonide, Hydrocortisone Butyrate, GCLE, Cefidinir, 头孢克肟,头孢地尼,氧氟沙星,左氧氟沙星,盐酸环丙沙星,盐酸克林霉素,拉索拉唑,奥美沙坦,替米沙Biboflavin-5-Phosphate Sodium, Methyltestosterone, Atenolol, Nimodipine, Argatroban, 坦,UDCA,尼扎替丁,伊贝沙坦, 氟比洛芬, 洛索洛芬钠, 美索巴莫, 瑞巴派特, 盐酸金刚烷胺, 盐酸安非 他酮, 盐酸多奈哌齐, 加巴贲丁, 氟苯尼考, 碘海醇, 氯霉素, 中间体, 化工品Cefixime, Cefdinir, 浙江横店普洛进出口有限公司/Zhejiang Hengdian Ofloxacin, Levofloxacin, Ciprofloxacin HCl, Clindamycin Hydrochloride, Lansoprazole, E1H20 Apeloa Imp. &Exp. Co., Ltd. Olmesartan, Telmisartan, UDCA, Nizatidine, Irbesartan, Flurbiprofen, Loxoprofen sodium, Methocarbamol, Rebamipide, Amantadine Hydrochloride, Bupropion Hydrochloride, Donepezil Hydrochloride, Gabapentin, Florfenicol, Iohexol, Chloramphenicol, Intermediates, Chemicals.Cefixime, Cefdinir, Ofloxacin, Levofloxacin, Ciprofloxacin HCl, 赛诺菲（中国）投资有限公司上海分公司 E1H22 /Sanofi(China)Investment Co., Ltd. Shanghai 安徽贝克联合制药有限公司/Anhui Biochem United E1H28 拉米夫定0 Pharmaceutical Co.,Ltd. Medieye Holding Co., Limited E1H29 Chiral Quest (Suzhou) Co., Ltd E1H32 Chunghwa Chemical Synthesis & Biotech Co., E1H37a Ltd. Chirogate International Inc. E1H37b Amano Enzyme China Ltd E1H38 Granules India Ltd E1H57 APC Pharmaceutical & Chemical Ltd E1J37 SCI Pharmtech, Inc E1J38 Morepen Laboratories Ltd E1J55 盐酸克林霉素,盐酸克林霉素棕榈酸酯,克林霉素磷酸酯Clindamycin HCl,Clindamycin Palmitate 浙江海翔药业销售有限公司/Zhejiang Hisoar E1K01 HCl,Clindamycin PhosphateClindamycin HCl,Clindamycin Palmitate HCl,Clindamycin Pharmaceutical sales Co.,Ltd. Phosphate 苯磺阿曲库铵,酒石酸布托啡诺,卡培他滨,醋酸卡泊芬净,塞来昔布,苯磺顺阿曲库铵,硫酸氢氯吡格雷, 达托霉素,地氟烷,盐酸右美托咪定,三水多西他赛,碘化油,依托泊苷,钆特酸葡胺,异环磷酰胺,碘克沙 醇,碘佛醇,盐酸伊立替康,盐酸氯胺酮,来曲唑,美司钠,奥美沙坦,奥沙利铂,七氟烷,替加氟,替莫唑胺,托 江苏恒瑞医药股份有限公司/Jiangsu Hengrui 伐普坦,卡莫司汀,度他雄胺,钆布醇,碘海醇,注射用醋酸卡泊芬净,注射用苯磺顺阿曲库铵,吸入用地氟 E1K08 Medicine Co., Ltd. 烷,多西他赛注射液,方达帕鲁注射液,加巴喷丁胶囊,盐酸伊立替康注射液,来曲唑片,奥沙利铂注射液, 注射用奥沙利铂,吸入用七氟烷,盐酸右美托咪定注射液,盐酸托伐普坦片,注射用塞替派,甲磺酸阿帕 替尼片,碘化油注射液,培门冬酶注射液,替吉奥胶囊,注射用替莫唑胺,注射用唑来膦酸,卡培他滨片,注 射用达托霉素,碘克沙醇注射液,碘海醇注射液,碘佛醇注射液Atracurium Besylate,Butorphanol 维生素E,生物素,辅酶Q10, 盐酸万古霉素,替考拉宁,米格列醇, 达托霉素, 替加环素Vitamin E,D- 浙江医药股份有限公司/Zhejiang Medicine Co., Ltd. E1K12 Biotin, CoQ10, Vancomycin HCl, Teicoplanin, Miglitol, Daptomycin, TigecyclineVitamin E,D- Biotin, CoQ10, Vancomycin HCl, Teicoplanin, Miglitol, Daptomycin, Tigecycline 更昔洛韦钠针剂,阿奇霉素针剂,左乙拉西坦针剂,依替巴肽针剂,泮托拉唑钠针剂,万古霉素针剂,伏立 康唑针剂,特利加压素针剂,阿昔洛韦针剂,硝普钠针剂,比伐卢定针剂,达托霉素针剂,塞替派针剂,林可 霉素针剂,阿奇霉素干混,地氯雷他定片/干混,双膜嘧啶片Ganciclovir Sodium for Injection 海南普利制药股份有限公司/Hainan Poly Pharm ,Azithromycin for Injection ,Levetiracetam Injection ,Pantoprazole Sodium for Injection E1K16 Co., Ltd ,Eptifibatide Injection ,Vancomycin for Injection,Voriconazole for Injection,Terlipressin Injection,Acyclovir Injection,Sodium Nitroprusside for Injection,Bivalirudin for Injection,Daptomycin for Injection,Esomeprazole Sodium for Injection,Doxycycline for 克拉维酸钾二氧化硅Injection,Amiodarone 1:1 Hydrochloride克拉维酸钾微晶纤维素 Injection,Cyclophosphamide 1:1 阿莫西林克拉维酸钾 2:1for 阿莫西林克拉维酸钾Injection,Thiotepa 4:1 阿莫西林克拉维酸钾 7:1 阿莫西林钠克拉维酸钾 5:1 头孢氨苄 头孢羟氨苄 头孢噻肟钠 头孢唑林 钠 头孢替唑钠 头孢哌酮钠 头孢呋辛钠 头孢曲松钠 7-氨基头孢烷酸 去乙酰-7-ACA 头孢他啶二盐 国药集团威奇达药业有限公司/Sinopharm Weiqida 酸盐 7-APRA 头孢噻肟酸 Potassium Clavulanate with Syloid 1:1 Potassium Clavulanate with E1K18 Pharmaceutical Co.,Ltd. Avicel 1:1 Amoxicillin with Potassium Clavulanate 2:1 Amoxicillin with Potassium Clavulanate 4:1 Amoxicillin with Potassium Clavulanate 7:1 Amoxicillin Sodium with Potassium Clavulanate 5:1 Cefalexin Cefadroxil Cefotaxime Sodium Cefazolin Sodium Ceftezole Sodium Cefoperazone Sodium Cefuroxime Sodium Ceftriaxone sodium 7-ACA China Chinopharma Ltd. E1K20 --- 原料药：扑热息痛粉，扑热息痛颗粒，厄多司坦，高半胱氨酸硫内酯，橙皮甙，氨基葡萄糖硫酸 盐，葡萄糖酸盐，水飞蓟素等。制剂和片剂：聚明胶肽，法莫替丁，头孢泊肟酯，葡萄糖酸钙氯化 钠，葡萄糖氯化钠，苯磺酸氨氯地平片等。API: Paracetamol, Paracetamol DC, 浙江康乐药业股份有限公司/ZHEJIANG KANGLE Erdosteine,Homocysteine thiolactone, hesperidin,Glucosamine E1K26 PHARMACEUTICAL CO.,LTD. sulfate,gluconate,silymarin I etc..Preparation and tablets: Polygeline Injection, famotidine, Cefpodoxime Proxetil Tablets, Dextrose and Sodium Chloride Injection, Dextrose and Sodium Chloride Injection, Amlodipine besylate tablets, etc..API: Paracetamol, Paracetamol DC, Erdosteine,Homocysteine thiolactone, 东阳光/HEC E1K28 111 Lipoid AG E1K32 Alkaloids Corporation E1K35 江苏圣泰科合成化学有限公司/Synthetics China E1K51 CO.,LTD. VIRCHOW GROUP E1M32 F.I.S. Fabbrica Italiana Sintetici SpA E1M35 Angelini A.C.R.A.F SPA E1M36 Lusochimica S.P.A. E1M40 Chemcon Speciality Chemicals Private Limited E1M51 Dipharma Francis S.r.l E1M53 RCA KG E1M56 Indukern Hong Kong Limited E1M57 主营医药原料及其制剂,医药中间体及化学试剂、生化药品、中药材、中成药、生物制品、医药新 技术以及有关医药来料加工、补偿贸易、合作生产业务等。Chinese Medical herbs,Chinese 上海市医药保健品进出口有限公司/Shanghai Palent drugs,Health products,Pharmaceuticals and their preparations, pharmaceutical Medicines & Health Products Import & Export E1N01 intermediates,Chemical reagents,Biopreparations, Biochemical pharmaceuticals Co., Ltd. etc.Chinese Medical herbs,Chinese Palent drugs,Health products,Pharmaceuticals and their preparations, pharmaceutical intermediates,Chemical reagents,Biopreparations, Biochemical pharmaceuticals etc. 强力霉素,林可霉素,硫酸新霉素,维生素A,维生素B,维生素C,维生素D,三氯蔗糖,萘普生,克拉霉素,扑 热息痛,非那西汀Doxycycline Hcl,Lincomycin,Neomycin sulphate,Vitamin A,Vitamin 华中药业有限公司/Huazhong Pharmaceutical B,Vitamin C,Vitamin E1N10 Co., Ltd. D,Sucralose,Naproxen,Clarithromycin,Paracetamol,PhenacetinDoxycycline Hcl,Lincomycin,Neomycin sulphate,Vitamin A,Vitamin B,Vitamin C,Vitamin D,Sucralose,Naproxen,Clarithromycin,Paracetamol,Phenacetin 南方制药,多西他赛,10-DAB III,GMP证书,美国FDA认证.,紫杉醇,GMP药厂,盐酸苯达莫司汀,来曲唑, 伊马替尼south pharma,Docetaxel,10-DAB III,GMP certificate,USFDA 福建南方制药股份有限公司/Fujian South E1N12 inspection,Paclitaxel,GMP plant,Bendamustine HCl,Letrozole,IImatinib mesylatesouth Pharmaceutical Co., Ltd. pharma,Docetaxel,10-DAB III,GMP certificate,USFDA inspection,Paclitaxel,GMP plant,Bendamustine HCl,Letrozole,IImatinib mesylate 数据完整性保障FDA/EMA/CFDA的合规咨询（预审评估,偏差管理,整改计划与实现）工艺设备和 公用设施的确认实验室合规服务工程设计和支持第三方审计产品法规注册Data Intergrity Assurance---Computerized System ValidationFDA/EMA/CFDA Compliance Service (Mock 上海彼科意企业管理咨询有限公司/PQE Consulting Audit, Inspection Preparation, Gap management, Remediation Planing and E1N18 (Shanghai) Excuting)Process Equipment & Utilities QualificationLaboratory Compliance ServiceEngineering Design & ComplianceThird Party AuditRegulatory AffairsData Intergrity Assurance---Computerized System ValidationFDA/EMA/CFDA Compliance Service (Mock Audit, Inspection Preparation, Gap management, Remediation Planing and Panexcell Clinical Lab Private Limited E1N22 SUANFARMA Group E1N24 United States Pharmacopeia Standard R&D and E1N26 Technical Polpharma E1N28 Council of Euope - EDQM E1N32 Amarantine Pharmaceutical LLC E1N38 RAFICHEM E1N53 Shenzhen Haibin Pharmaceutical Co., Ltd. E1P01 丽珠医药集团股份有限公司/Livzon Pharmaceutical E1P01 Group Inc. Shin Nippon Yakugyo Co., Ltd E1P02 FMC Corporation E1P03 阿卡波糖、硫酸博莱霉素、环磷酰胺、阿糖胞苷、盐酸多柔比星、盐酸表柔比星、氟达拉滨磷酸酯 、盐酸吉西他滨、盐酸格拉司琼、伊维菌素、来曲唑、洛伐他汀、甲氨蝶呤、丝裂霉素、莫西克汀 、普伐他汀钠、吡喹酮、辛伐他汀、酒石酸长春瑞宾Acarbose、Bleomycin Sulfate、 浙江海正药业股份有限公司/Zhejiang Hisun Pharma. Cyclophosphamide、Cytarabine、Doxorubicin HCL、Epirubicin Hydrochloride、 E1P16 Co., Ltd. Fludarabine Phosphate、Gemcitabine Hydrochloride、Granisetron HCl、Ivermectin、 Letrozole、Lovastatin、Methotrexate、Mitomycin、Moxidectin、Pravastain
Load more

Recommended publications
  • Oral Antifungal Agent Nailin® Capsules 100Mg Approved in Japan
    FOR IMMEDIATE RELEASE January 19, 2018 Sato Pharmaceutical Co., Ltd. Eisai Co., Ltd. ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN Sato Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Seiichi Sato, “Sato Pharma”) obtained marketing and manufacturing approval for the oral antifungal agent NAILIN® Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (“fosravuconazole”) for the treatment of onychomycosis in Japan on January 19, 2018. Sato Pharma and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) are jointly providing information on its proper use. Fosravuconazole, the active ingredient of NAILIN® Capsules 100mg, is a new triazole class oral antifungal component discovered by Eisai. Sato Pharma conducted a Phase III clinical study of the agent in patients with onychomycosis in Japan, and after confirming efficacy and safety of the agent in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017. Onychomycosis affects 1 in every 10 Japanese people, and there are an estimated approximately 11 million sufferers in Japan. With Sato Pharma now having obtained marketing and manufacturing approval for NAILIN® Capsules 100mg, as an oral treatment for onychomycosis, this is the first new treatment for the disease in approximately 20 years. By providing NAILIN® Capsules 100mg as a new option for the treatment of onychomycosis, Sato Pharma and Eisai will strive to fulfil the needs of onychomycosis patients and healthcare professionals.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • R&D Model & Portfolio
    R&D MODEL & PORTFOLIO ADAPTED TREATMENTS FOR THE BENEFIT OF NEGLECTED PATIENTS The R&D strategies developed by DNDi since its inception aim to Phase II trials as a potential single- address the immediate needs of patients by improving existing dose oral treatment and is the first therapeutic options in the short term, whilst undertaking longer molecule to arise from DNDi’s lead term research to identify and develop entirely new compounds optimization programme. which will be valuable adapted tools, particularly for elimination targets set by the World Health Organization. Although not Leishmaniasis is a complex family necessarily breakthrough medicines, six new treatments have of diseases, and the identification been delivered to date as a result of the short-term strategy, of new compounds has proved which have brought significant benefits to patients. challenging. Compound libraries from a variety of sources have been screened and, despite the inevitable The year 2015 has been a turning are orally available compounds for loss of compounds to attrition, NCEs point for DNDi, as long-term systemic use. The most clinically from the nitroimidazole, oxaborole, investments have now filled the advanced of these are for sleeping and aminopyrazole chemical drug development pipeline with sickness: fexinidazole, which was families are undergoing lead thirteen new chemical entities identified from compound mining optimization to combat Leishmania (NCEs) included by the end of the and is a ten day oral treatment, infections, with the nitroimidazole year, the vast majority of which and SCYX-7158, which is entering VL-0690 selected to go forward to 14 › DNDi Annual Report 2015 R&D MODEL & PORTFOLIO pre-clinical development in 2015.
    [Show full text]
  • Minutes of the 612Thmeeting Ofthe State
    Minutes of the 612thmeeting ofthe State Level Expert Appraisal Committee(SEAC) held on 18/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 612thmeeting of the State Level Expert Appraisal Committee (SEAC) was held on 18th March 2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri V. N. Patel, Member, SEAC 4. Shri. R. J. Shah, Member, SEAC 5. Shri A. K. Muley, Member, SEAC 6. Dr. V. K. Jain, Member, SEAC 7. Shri A. V. Shah, Secretary, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR / EC – Reconsiderationcases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 1 SIA/GJ/IND2/27657/2018 M/s. Lincoln Pharmaceutical Limited Appraisal Block No. 176 (old Block No. 95/5-B), At – Khatraj, Ta. Kalol, Dist. Gandhinagar. Category of the unit: 5(f) Project status: New Project proponent (PP) has submitted online application vide no. SIA/GJ/IND2/27657/2018 on dated 05/11/2019 for obtaining Environmental Clearance. The SEAC had recommended TOR to SEIAA and SEIAA issued TOR to PP vide their letter dated 30/10/2018. Project proponent has submitted EIA Report prepared by M/s. Bhagwati Enviro Care Pvt. Ltd., Ahmedabad based on the TOR issued by SEIAA. Public Hearing of the Project was conducted by Gujarat Pollution Control Board at Project Site of M/s.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Fosravuconazole L-Lysine Ethanolate | Medchemexpress
    Inhibitors Product Data Sheet Fosravuconazole L-lysine ethanolate • Agonists Cat. No.: HY-16779B CAS No.: 914361-45-8 Molecular Formula: C₃₁H₄₀F₂N₇O₈PS • Molecular Weight: 739.73 Screening Libraries Target: Fungal; Parasite Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (67.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic) (insoluble) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.3518 mL 6.7592 mL 13.5184 mL Stock Solutions 5 mM 0.2704 mL 1.3518 mL 2.7037 mL 10 mM 0.1352 mL 0.6759 mL 1.3518 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution BIOLOGICAL ACTIVITY Description Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. In Vitro Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus , and Trichophyton species[1]. MCE has not independently confirmed the accuracy of these methods.
    [Show full text]
  • Surveillance of Antifungal Use in Japan Oral Medicine + Injection Change in Antifungal Use for All of Japan by Rout of Administration 1
    Surveillance of antifungal use in Japan Oral medicine + Injection Change in antifungal use for all of Japan by rout of administration 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 Injection注射薬 内服薬Oral medicine(テルビナフィン・ホスラブコナゾールを除く (except for terbinafine and fosravuconazole) ) ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Oral medicine Change in antifungal use (oral medicine) for all of Japan 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 フルシトシンFlucytosine ボリコナゾールVoriconazole イトラコナゾールItraconazole フルコナゾールFluconazole ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Injection Change in antifungal use (injection) for all of Japan 0.035 / day 0.03 0.025 0.02 0.015 Dose / inhabitants / 1,000 Dose 0.01 Daily 0.005 Defined 0 2013 2014 2015 2016 2017 2018 2019 Amphotericinアムホテリシン BB ミコナゾールMiconazole フルコナゾールFluconazole イトラコナゾールItraconazole Voriconazoleボリコナゾール Caspofunginカスポファンギン ミカファンギンMicafungin 〇The data are calculated from claims registered in the NDB. The data do not always reflect the precise antibiotic use because the data of patients who receive publicly funded health care are not always included. The numerical values are different from those of the surveillance of antibiotic sales (http://amrcrc.ncgm.go.jp/surveillance/020/20190902163931.html) due to the different data source. 〇The figures indicate drug utilization standardized by defined daily dose (DDD) per population and drug, called DID (DDDs/1,000 inhabitants/day) (Reference:https://www.whocc.no/atc_ddd_index/ ).
    [Show full text]
  • Mining Sudanese Medicinal Plants for Natural Compounds Against Malaria and Neglected Tropical Diseases
    Mining Sudanese Medicinal Plants for Natural Compounds against Malaria and Neglected Tropical Diseases INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Abdelhalim Babiker Mohamed Mahmoud aus dem Sudan Basel, 2020 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Pascal Mӓser Prof. Dr. Thomas J. Schmidt Basel, den 23.06.2020 Prof. Dr. Martin Spiess Dekan To my father Who taught me that perseverance and hard work always pays off. May your inspiring soul rest in peace. Table of Contents Acknowledgment ...................................................................................................................................................... I Abbreviations .......................................................................................................................................................... III Summary .................................................................................................................................................................... V 1. INTRODUCTION: Neglected Tropical Diseases, Drug Discovery, and the Sudan .................... 1 1.1 Neglected Tropical Diseases ............................................................................................................................ 3 1.1.1 NTDs and Sudan .........................................................................................................................................
    [Show full text]
  • Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
    ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969
    [Show full text]
  • A Road Map for Neglected Tropical Diseases 2021–2030
    Buruli ulcer Chagas disease Dengue and chikungunya Ending the neglect to Dracunculiasis attain the Sustainable Echinococcosis Development Goals Foodborne trematodiases A road map for neglected Human African trypanosomiasis tropical diseases 2021–2030 Leishmaniasis Leprosy Lymphatic filariasis Mycetoma, chromoblastomycosis and other deep mycoses Onchocerciasis Rabies Scabies and other ectoparasitoses Schistosomiasis Soil-transmitted helminthiases Snakebite envenoming Taeniasis and cysticercosis Trachoma Yaws SECTION 01: CONTEXT AND PURPOSE OF THE ROAD MAP 01 Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 ISBN 978-92-4-001035-2 (electronic version) ISBN 978-92-4-001036-9 (print version) © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
    [Show full text]
  • The Activity of 2,3-Dimethylquinoxaline Against Madurella Mycetomatis
    American Journal of www.biomedgrid.com Biomedical Science & Research ISSN: 2642-1747 --------------------------------------------------------------------------------------------------------------------------------- Research Article Copy Right@ Abdelbagi Alfadil The Activity of 2,3-Dimethylquinoxaline against Madurella mycetomatis Abdelbagi Alfadil1*, Ahmed Shaker Ali2, Hamoud Alsamhan2,3, Huda Alkreathy2, Asif Jiman-Fa- tani1 and Hind Abdulmajed1 1Department of Microbiology and Medical Parasitology, King Abdulaziz University, Saudi Arabia 2Department of Pharmacology, King Abdulaziz University, Saudi Arabia 3College of Pharmacy, King Saud bin Abdulaziz University for Health Science, Saudi Arabia *Corresponding author: Abdelbagi Alfadil Mousa, Department of Microbiology and Medical Parasitology, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. To Cite This Article: Abdelbagi A, A Shaker Ali, H Alsamhan, H Alkreathy, A Jiman-Fatani. H Abdulmajed. The Activity of 2,3-Dimethylquinox- aline against Madurella mycetomatis. Am J Biomed Sci & Res. 2021 - 11(4). AJBSR.MS.ID.001654. DOI: 10.34297/AJBSR.2021.11.001654. Received: January 06, 2021; Published: January 18, 2021 Abstract Objective: Madurella mycetomatis is the most prevalent causative species of the eumycetoma, a chronic progressive neglected tropical disabling treatment is challenging, requires prolonged therapy, resulting in low cure rates and a high incidence of recurrence. Screening new compounds for antifungalinfectious diseaseactivity ofagainst the subcutaneous Madurella mycetomatis tissue. It carries is needed. a significant social and economic burden to the endemic areas. Unfortunately, the available Design: In vitro: the susceptibility of a Madurella mycetomatis of 2,3-dimethylquinoxaline 1% topical gel against the same strain was evaluated in the BALB/c mouse eumycetoma model (n=6; 6-8 weeks old). isolate toward the 2,3-dimethylquinoxaline was determined. In vivo: the efficacy Results: 2,3-Dimethylquinoxaline inhibited the growth of Madurella mycetomatis at MIC 312 µg/ml (1.9 mM).
    [Show full text]